SCHEMBL5768673

SCHEMBL5768673

O=C1CCC(C(=O)O)(c2cccc(F)c2)CC1

nearest known ligand 0.57

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
AKR1C1 Q04828 2/20 0.46
CYP2C9 P11712 3/20 0.43
MEN1 O00255 1/20 0.43
KMT2A Q03164 1/20 0.43
APP P05067 2/20 0.43
CYP2C19 P33261 2/20 0.43
CYP3A4 P08684 1/20 0.43
HCAR2 Q8TDS4 1/20 0.42
HSD11B1 P28845 1/20 0.42
AKR1C3 P42330 2/20 0.41
AKR1C2 P52895 2/20 0.41
OPRM1 P35372 1/20 0.40
OPRL1 P41146 1/20 0.40
CCR2 P41597 1/20 0.40
ELOVL1 Q9BW60 1/20 0.40
CYP2D6 P10635 1/20 0.40
KDM1A O60341 2/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13887009 0.92 AKR1C1 (0.41) AKR1C1CYP2C9MEN1KMT2AAPP
SCHEMBL301111 0.89 AKR1C1 (0.53) AKR1C1CYP2C9APPCYP2C19CYP3A4
SCHEMBL30487797 0.85 AKR1C1 (0.65) AKR1C1CYP2C9APPCYP2C19CYP3A4
SCHEMBL2079237 0.85 AKR1C1 (0.65) AKR1C1CYP2C9APPCYP2C19CYP3A4
SCHEMBL2535205 0.85 AKR1C1 (0.59) AKR1C1CYP2C9APPCYP2C19CYP3A4
SCHEMBL3219884 0.84 AKR1C1 (0.62) AKR1C1CYP2C9MEN1KMT2AAPP
SCHEMBL435932 0.84 AKR1C1 (0.62) AKR1C1CYP2C9MEN1KMT2AAPP
SCHEMBL17999491 0.81 HCAR2 (0.38) AKR1C1CYP2C9APPCYP2C19CYP3A4
SCHEMBL631791 0.81 AKR1C1 (0.68) AKR1C1CYP2C9MEN1KMT2ACYP2C19
SCHEMBL11832779 0.81 AKR1C1 (0.46) AKR1C1CYP2C9MEN1KMT2AHCAR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1286967-B1 CYCLOHEXANE DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS MERCK SHARP & DOHME (GB) 2006-09-27 EP disclosed
US-7105507-B2 Cyclohexane derivatives and their use as therapeutic agents MERCK SHARP & DOHME LIMITED (GB) 2006-09-12 US disclosed
US-20030236250-A1 Cyclohexane derivatives and their use as therapeutic agents MERCK SHARP & DOHME LTD. (GB) 2003-12-25 US disclosed
EP-1286967-A1 CYCLOHEXANE DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS MERCK SHARP & DOHME LTD. (GB) 2003-03-05 EP disclosed
WO-2001087838-A1 CYCLOHEXANE DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS MERCK SHARP & DOHME LIMITED (GB) 2001-11-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030236250-A1 Cyclohexane derivatives and their use as therapeutic agents CNR2, CNR1, HTR1A AKR1C1 1660/4885CYP2C9 973/4885MEN1 3255/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.